Publication | Open Access

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT

InflammationAutoimmune DiseaseMedicineVascular InflammationSystemic TreatmentImmunologyUstekinumab TreatmentClinical DermatologyAutoimmunityDermatologyFeasibility StudyPsoriatic Arthritis